BSE Live
Apr 17, 09:09Prev. Close
117.71
Open Price
117.68
Bid Price (Qty.)
117.68 (4)
Offer Price (Qty.)
120.15 (50)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of Godavari Drugs (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 4.84 | 2.06 | 0.64 | -2.12 | 0.01 | |
| Diluted EPS (Rs.) | 4.84 | 2.06 | 0.64 | -2.12 | 0.01 | |
| Cash EPS (Rs.) | 5.75 | 3.45 | 1.97 | -0.91 | 1.18 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 17.34 | 12.63 | 10.57 | 9.93 | 12.05 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 17.34 | 12.63 | 10.57 | 9.93 | 12.05 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 72.83 | 12.53 | 10.12 | 4.94 | 6.95 | |
| PBDIT/Share (Rs.) | 8.08 | 2.60 | 2.56 | -0.71 | 1.36 | |
| PBIT/Share (Rs.) | 7.17 | 1.21 | 1.23 | -1.93 | 0.18 | |
| PBT/Share (Rs.) | 6.29 | 0.93 | 0.96 | -2.12 | 0.01 | |
| Net Profit/Share (Rs.) | 4.84 | 2.06 | 0.64 | -2.12 | 0.01 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 11.08 | 20.77 | 25.25 | -14.46 | 19.52 | |
| PBIT Margin (%) | 9.84 | 9.65 | 12.15 | -39.07 | 2.65 | |
| PBT Margin (%) | 8.63 | 7.44 | 9.43 | -42.95 | 0.12 | |
| Net Profit Margin (%) | 6.64 | 16.44 | 6.32 | -42.95 | 0.09 | |
| Return on Networth / Equity (%) | 27.92 | 16.31 | 6.05 | -21.35 | 0.05 | |
| Return on Capital Employed (%) | 20.68 | 12.78 | 4.38 | -16.43 | 0.04 | |
| Return on Assets (%) | 10.49 | 10.09 | 3.22 | -10.37 | 0.03 | |
| Total Debt/Equity (X) | 0.65 | 0.25 | 0.30 | 0.28 | 0.15 | |
| Asset Turnover Ratio (%) | 157.87 | 61.36 | 50.99 | 24.14 | 37.42 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.57 | 2.10 | 1.84 | 1.30 | 1.87 | |
| Quick Ratio (X) | 1.03 | 1.16 | 1.05 | 0.66 | 0.98 | |
| Inventory Turnover Ratio (X) | 5.91 | 3.11 | 2.43 | 1.02 | 1.74 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 100.00 | 100.00 | 100.00 | 0.00 | 100.00 | |
| Cash Earnings Retention Ratio (%) | 100.00 | 100.00 | 100.00 | 0.00 | 100.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 48.43 | 9.98 | 8.22 | 5.57 | 5.54 | |
| EV/Net Operating Revenue (X) | 0.88 | 1.06 | 1.08 | 1.50 | 1.06 | |
| EV/EBITDA (X) | 7.96 | 5.09 | 4.27 | -10.35 | 5.42 | |
| MarketCap/Net Operating Revenue (X) | 0.73 | 0.83 | 0.80 | 0.97 | 0.83 | |
| Retention Ratios (%) | 100.00 | 100.00 | 100.00 | 0.00 | 100.00 | |
| Price/BV (X) | 3.08 | 0.82 | 0.77 | 0.48 | 0.48 | |
| Price/Net Operating Revenue | 0.73 | 0.83 | 0.80 | 0.97 | 0.83 | |
| Earnings Yield | 0.09 | 0.20 | 0.08 | -0.44 | 0.00 |
25.02.2026
Godavari Drugs Standalone December 2025 Net Sales at Rs 22.18 crore, down 24.93% Y-o-Y
24.11.2025
Godavari Drugs Standalone September 2025 Net Sales at Rs 26.65 crore, up 2.15% Y-o-Y
10.06.2025
Godavari Drugs Standalone March 2025 Net Sales at Rs 25.50 crore, down 34% Y-o-Y
17.02.2025
Godavari Drugs Standalone December 2024 Net Sales at Rs 29.55 crore, down 31.45% Y-o-Y
25.02.2026
Godavari Drugs Standalone December 2025 Net Sales at Rs 22.18 crore, down 24.93% Y-o-Y
24.11.2025
Godavari Drugs Standalone September 2025 Net Sales at Rs 26.65 crore, up 2.15% Y-o-Y
10.06.2025
Godavari Drugs Standalone March 2025 Net Sales at Rs 25.50 crore, down 34% Y-o-Y
17.02.2025
Godavari Drugs Standalone December 2024 Net Sales at Rs 29.55 crore, down 31.45% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth